As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Dupilumab in the treatment of asthma with Type 2 inflammation.
This review discusses pathogenesis of asthma and type 2 inflammation and phenotypes, evidence in support of the use of Dupilumab, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Peter Wark, a senior staff specialist in Respiratory and Sleep Medicine at John Hunter Hospital and a conjoint Professor with the University of Newcastle
Please login below to download this issue (PDF)